Facebook
X
LinkedIn
Forward
Integrating Radiation Therapy with Novel Immunotherapies in the Management of Brain Metastases and Leptomeningeal Disease
With improved systemic therapy, the management of brain metastasis has become increasingly important. A number of immunotherapies and targeted agents have shown blood brain barrier penetration with a potential role in the upfront management of brain metastases and leptomeningeal disease. Given new systemic options for brain metastases, coordinated care between radiation oncologists, medical oncologists, neuro-oncologists, and neurosurgeons is critical to optimize intracranial control but also limit toxicity. In this activity, a multidisciplinary panel guides the audience through novel immunotherapies in the management of brain metastases and leptomeningeal disease and provide insight on sequencing, management of toxicities, and response assessment.
Topics:
- Systemic Immunotherapies in the Management of Brain Metastases
Solmaz Sahebjam, MD - Remodeling the Immune Microenvironment of Leptomeningeal Disease Using Dendritic Cell Therapy: Promoting Adaptive Immune Responses
Peter Forsyth, MD - Optimizing Radiation Delivery of Brain Metastases and Leptomeningeal Disease Alongside Immunotherapies
Zachary Scott Buchwald, MD, PhD - Q and A
Kamran Ali Ahmed, MD - Moderator
Full Panel
This activity is available from January 27, 2026, through 11:59 p.m. Eastern time on January 26, 2028.
The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, radiation biologists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify systemic agents with demonstrated intracranial activity and ongoing clinical trials.
- Optimize treatment sequencing with response assessment of novel immunotherapies.
- Identify ways in which to identify and potentially reduce risks of radiation necrosis alongside immunotherapies.
Moderator:
- Kamran Ali Ahmed, MD, is employed by Moffitt Cancer Center. Dr. Ahmed receives grant/research funding from Eli Lilly, Genentech and Gilead.
Presenters:
- Solmaz Sahebjam, MD, is employed by Johns Hopkins University. Dr. Sahebjam receives compensation/payment from Telix Pharmaceuticals and Pilant Therapeutics.
- Peter Forsyth, MD, is employed by Moffitt Cancer Center. Dr. Forsyth receives compensation/payment from Novocure, BTG, Inovio, AbbVie, Ziopharm, Tocagen, Pfizer and Celgene.
- Zachary Scott Buchwald, MD, PhD, is employed by Emory University. Dr. Buchwald has no relevant financial relationship with ineligible companies.
Planners:
- Malcolm Mattes, MD is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies.
- Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies.
- Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
- Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems.
- Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical.
All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
- Nonmember: $149
- Member: $99
- Member-in-Training: $49
- Student/Graduate Student/PGY-1 Member: $49
- Postdoctoral Fellow Member: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until January 26, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.